Pulse Prescription drugs has acquired approval for its nano-carrier entrapped Vitamin D3 oral dispersion from the Medication Controller Normal of India (DCGI).
The approval transforms superior nano pharmaceutical analysis right into a regulated, patient-ready product, the corporate mentioned on Thursday.
Founder and Managing Director Okay. V. Rambabu mentioned such an approval might be first on the earth. It’s set to pave the best way Pulse Prescription drugs to take the product to a number of the neighbouring South Asian international locations apart from serving to it in in search of regulatory approval in extremely regulated markets, together with the U.S.
The corporate, which he mentioned has been working in nano pharmaceutical drug supply since 2010 mentioned makes use of nanotechnology to enhance how nicely a drug works, its bioavailability, how simply it’s tolerated and the general affected person expertise. It has developed a number of proprietary platform applied sciences to successfully ship medicines.
Past Vitamin D3, Pulse is making use of these platforms to different important vitamins akin to Vitamin K2-7, Vitamin B12 and Iron in addition to in broadly used drugs like Paracetamol, Diclofenac and Ibuprofen, he mentioned.
The corporate mentioned it holds 5 patents throughout India, the U.S., Russia, Mexico and Australia. An EU patent for its Aqueol know-how is within the last levels of approval.
It has additionally has filed patents for 4 different proprietary platforms throughout 7 main international locations and dealing on submitting 3 extra. “Our goal has at all times been to establish essential unmet wants in drug supply and develop sensible options that may make a significant distinction to sufferers,” Mr.Rambabu mentioned.
Revealed – August 20, 2026 09:41 pm IST
